APG Asset Management N.V. Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

APG Asset Management N.V. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 119.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,229,769 shares of the biopharmaceutical company's stock after acquiring an additional 670,236 shares during the period. APG Asset Management N.V. owned about 0.10% of Gilead Sciences worth $109,699,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership purchased a new position in shares of Gilead Sciences in the 4th quarter worth $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter worth $29,000. Crews Bank & Trust purchased a new stake in Gilead Sciences during the fourth quarter valued at $31,000. Finally, Stephens Consulting LLC lifted its holdings in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 260 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GILD. BMO Capital Markets upped their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Morgan Stanley upped their price objective on Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 11th. Finally, Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $105.12.

Remove Ads

Gilead Sciences Price Performance

Gilead Sciences stock traded up $2.23 during midday trading on Friday, reaching $103.63. 8,683,683 shares of the stock traded hands, compared to its average volume of 7,493,897. The stock has a market cap of $129.04 billion, a P/E ratio of 280.08, a PEG ratio of 0.71 and a beta of 0.32. The stock's fifty day moving average is $108.34 and its 200-day moving average is $96.79. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 3.05%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. Gilead Sciences's dividend payout ratio is currently 854.05%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders sold 302,785 shares of company stock valued at $30,503,250. Insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.